LivaNova (LIVN) Downgraded by BidaskClub

BidaskClub downgraded shares of LivaNova (NASDAQ:LIVN) from a strong-buy rating to a buy rating in a report released on Thursday.

A number of other analysts have also issued reports on LIVN. Needham & Company LLC reaffirmed a buy rating and issued a $135.00 target price (up previously from $128.00) on shares of LivaNova in a report on Wednesday, August 1st. Stifel Nicolaus reaffirmed a buy rating and issued a $135.00 target price on shares of LivaNova in a report on Thursday, August 2nd. Zacks Investment Research lowered LivaNova from a buy rating to a hold rating in a report on Thursday, September 20th. Jefferies Financial Group raised their target price on LivaNova to $150.00 and gave the company a buy rating in a report on Tuesday, October 2nd. Finally, BTIG Research reaffirmed a hold rating on shares of LivaNova in a report on Thursday, November 1st. Three equities research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company’s stock. The stock currently has an average rating of Buy and a consensus target price of $126.50.

Shares of LIVN stock traded up $0.87 during trading on Thursday, reaching $99.13. The company had a trading volume of 11,853 shares, compared to its average volume of 694,115. The company has a debt-to-equity ratio of 0.06, a quick ratio of 1.21 and a current ratio of 1.65. LivaNova has a one year low of $76.14 and a one year high of $131.54. The company has a market capitalization of $4.78 billion, a price-to-earnings ratio of 29.96, a PEG ratio of 3.07 and a beta of 0.94.

LivaNova (NASDAQ:LIVN) last issued its quarterly earnings data on Wednesday, October 31st. The company reported $0.82 earnings per share for the quarter, missing the Zacks’ consensus estimate of $0.90 by ($0.08). LivaNova had a negative net margin of 8.31% and a positive return on equity of 8.77%. The company had revenue of $272.10 million during the quarter, compared to the consensus estimate of $275.03 million. During the same period in the previous year, the business posted $0.83 earnings per share. The firm’s revenue was up 8.3% on a year-over-year basis. On average, analysts forecast that LivaNova will post 3.1 EPS for the current fiscal year.

In other news, Director Daniel Jeffrey Moore sold 1,000 shares of LivaNova stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $116.68, for a total transaction of $116,680.00. The sale was disclosed in a document filed with the SEC, which is available at this hyperlink. Also, insider David S. Wise sold 1,500 shares of LivaNova stock in a transaction that occurred on Thursday, November 15th. The stock was sold at an average price of $119.23, for a total value of $178,845.00. The disclosure for this sale can be found here. Insiders sold a total of 8,500 shares of company stock worth $1,002,355 in the last ninety days. Insiders own 0.41% of the company’s stock.

Large investors have recently made changes to their positions in the company. grace capital acquired a new stake in shares of LivaNova during the 2nd quarter worth approximately $100,000. Harvest Fund Management Co. Ltd acquired a new stake in shares of LivaNova during the 3rd quarter worth approximately $108,000. Bamco Inc. NY acquired a new stake in shares of LivaNova during the 3rd quarter worth approximately $143,000. Envestnet Asset Management Inc. lifted its position in shares of LivaNova by 1,054.2% during the 2nd quarter. Envestnet Asset Management Inc. now owns 1,662 shares of the company’s stock worth $166,000 after buying an additional 1,518 shares during the period. Finally, Gilder Gagnon Howe & Co. LLC bought a new position in shares of LivaNova during the 3rd quarter worth approximately $167,000. 82.26% of the stock is currently owned by institutional investors.

About LivaNova

LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates in two segments, Cardiac Surgery and Neuromodulation. The Cardiac Surgery segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, perfusion tubing systems, cannulae and accessories for extracorporeal circulation, and systems for autotransfusion and autologous blood washing, as well as surgical tissue and mechanical heart valve replacements, and repair products for damaged or diseased heart valves.

Featured Article: Stock Symbol

Analyst Recommendations for LivaNova (NASDAQ:LIVN)

Receive News & Ratings for LivaNova Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for LivaNova and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply